# A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

> **NCT02667236** · PHASE3 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 450 (actual)

## Conditions studied

- Seborrheic Keratosis

## Interventions

- **DRUG:** A-101 Solution
- **OTHER:** Vehicle Solution

## Key facts

- **NCT ID:** NCT02667236
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2018-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02667236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02667236, "A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02667236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*